Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor γ synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells

Cancer Letters

Volumn 275, Issue 2, 2009, Pages 247-255

  Sun, Wei Hao ^a   Chen, Guo Sheng ^a   Ou, Xi Long ^b   Yang, Ye ^c   Luo, Cheng ^d,e   Zhang, Yuan ^a   Shao, Yun ^a   Xu, Hai Chen ^a   Xiao, Bin ^a   Xue, Yi Ping ^a   Zhou, Su Ming ^a   Zhao, Qin Shi ^d   Ding, Guo Xian ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^d KUNMING INSTITUTE OF BOTANY   (China)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

Apoptosis; Cyclooxygenase 2; Pancreatic cancer; Peroxisome proliferators activated receptor ; Proliferation

Indexed keywords

CYCLINE; CYCLOOXYGENASE 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BAX; PROTEIN BCL 2; ROSIGLITAZONE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMUNOHISTOCHEMISTRY; NITROBENZENES; PANCREATIC NEOPLASMS; PPAR GAMMA; PROLIFERATING CELL NUCLEAR ANTIGEN; SULFONAMIDES; THIAZOLIDINEDIONES;

EID: 59349085139     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.10.023     Document Type: Article

References (53)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M.J. Cancer statistics, 2005. CA Cancer J. Clin. 55 2005 (2005) 10-30
2. McKenna S., and Eatock M. The medical management of pancreatic cancer: a review. Oncologist 8 (2003) 149-160
3. Williams C.S., Smalley W., and DuBois R.N. Aspirin use and potential mechanisms for colorectal cancer prevention. J. Clin. Invest. 100 (1997) 1325-1329
4. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342 (2000) 1946-1952
5. Smith W.L., Meade E.A., and DeWitt D.L. Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann. NY Acad. Sci. 714 (1994) 136-142
6. Molina M.A., Sitja-Arnau M., Lemoine M.G., Frazier M.L., and Sinicrope F.A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 59 (1999) 4356-4362
7. Yip-Schneider M.T., Barnard D.S., Billings S.D., Cheng L., Heilman D.K., Lin A., Marshall S.J., Crowell P.L., Marshall M.S., and Sweeney C.J. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 21 (2000) 139-146
8. Franco L., Doria D., Bertazzoni E., Benini A., and Bassi C. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer. Prostaglandins Other Lipid Mediat. 73 (2004) 51-58
9. Crowell P.L., Schmidt C.M., Yip-Schneider M.T., Savage J.J., Hertzler II D.A., and Cummings W.O. Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia. Neoplasia 8 (2006) 437-445
10. Ding X.Z., Tong W.G., and Adrian T.E. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 20 (2000) 2625-2631
11. Tseng W.W., Deganutti A., Chen M.N., Saxton R.E., and Liu C.D. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J. Gastrointest. Surg. 6 (2002) 838-844
12. Zweifel B.S., Davis T.W., Ornberg R.L., and Masferrer J.L. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res. 62 (2002) 6706-6711
13. Eibl G., Reber H.A., Wente M.N., and Hines O.J. The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 26 (2003) 33-41
14. Han C., Leng J., Demetris A.J., and Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res. 64 (2004) 1369-1376
15. Wick M., Hurteau G., Dessev C., Chan D., Geraci M.W., Winn R.A., Heasley L.E., and Nemenoff R.A. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol. Pharmacol. 62 (2002) 1207-1214
16. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K., and Chen C.S. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 94 (2002) 585-591
17. Reddy B.S., Kawamori T., Lubet R.A., Steele V.E., Kelloff G.J., and Rao C.V. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res. 59 (1999) 3387-3391
18. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., and Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other nonsteroidal anti-inflammatory drugs. J. Biol. Chem. 272 (1997) 3406-3410
19. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
20. Eibl G., Wente M.N., Reber H.A., and Hines O.J. Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis. Biochem. Biophys. Res. Commun. 287 (2001) 522-529
21. Koeffler H.P. Peroxisome proliferator-activated receptor gamma and cancers. Clin. Cancer Res. 9 (2003) 1-9
22. Elnemr A., Ohta T., Iwata K., Ninomia I., Fushida S., Nishimura G., Kitagawa H., Kayahara M., Yamamoto M., Terada T., and Miwa K. PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int. J. Oncol. 17 (2000) 1157-1164
23. Motomura W., Okumura T., Takahashi N., Obara T., and Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human pancreatic carcinoma cells. Cancer Res. 60 (2000) 5558-5564
24. Motomura W., Nagamine M., Tanno S., Sawamukai M., Takahashi N., Kohgo Y., and Okumura T. Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. J. Gastroenterol. 39 (2004) 461-468
25. Farrow B., O'Connor K.L., Hashimoto K., Iwamura T., and Evers B.M. Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator. Surgery 134 (2003) 206-212
26. Shirota T., Haji S., Yamasaki M., Iwasaki T., Hidaka T., Takeyama Y., Shiozaki H., and Ohyanagi H. Apoptosis in human pancreatic cancer cells induced by eicosapentaenoic acid. Nutrition 21 (2005) 1010-1017
27. Dong Y.W., Wang X.P., Wu K., Wu L.Y., and Zhang R.L. Regulatory effects of peroxisome proliferator-activated receptor gamma on the growth of pancreatic carcinoma. Zhonghua Nei Ke Za Zhi 42 (2003) 479-482 (in Chinese)
28. Kyriazis A.P., McCombs III W.B., Sandberg A.A., Kyriazis A.A., Sloane N.H., and Lepera R. Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mouse. Cancer Res. 43 (1983) 4393-4401
29. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
30. 2 synthesis in rat gastric epithelial cells in vitro. J. Gastroenterol. Hepatol. 21 (2006) 754-758
31. Dolinsky T.J., Nielsen J.E., McCammon J.A., and Baker N.A. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 32 (2004) W665-667
32. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19 (1998) 1639-1662
33. Koopman G., Reutelingsperger C.P., Kuijten G.A., Keehnen R.M., Pals S.T., and van Oers M.H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84 (1994) 1415-1420
34. Tsurimoto T. PCNA, a multifunctional ring on DNA. Biochim. Biophys. Acta 1443 (1998) 23-39
35. Bravo R., Frank R., Blundell P.A., and MacDonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase delta. Nature 326 (1987) 515-517
36. Grösch S., Tegeder I., Niederberger E., Bräutigam L., and Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15 (2001) 2742-2744
37. Amrite A.C., and Kompella U.B. Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. J. Pharmacol. Exp. Ther. 324 (2008) 749-758
38. Sun W.H., Zhu F., Chen G.S., Su H., Luo C., Zhao Q.S., Zhang Y., Shao Y., Sun J., Zhou S.M., Ding G.X., and Cheng Y.L. Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis, and inhibits the proliferation of human gastric cancer cells in vitro. Cancer Lett. 263 (2008) 302-311
39. Aly A., Shulkes A., and Baldwin G.S. Gastrins, cholecystokinins and gastrointestinal cancer. Biochim. Biophys. Acta 1704 (2004) 1-10
40. Morisset J., Lainé J., Biernat M., and Julien S. What are the pancreatic target cells for gastrin and its CCKB receptor? Is this a couple for cancerous cells?. Med. Sci. Monit. 10 (2004) RA242-RA246
41. Monstein H.J., Ohlsson B., and Axelson J. Differential expression of gastrin, cholecystokinin-A and cholecystokinin-B receptor mRNA in human pancreatic cancer cell lines. Scand. J. Gastroenterol. 36 (2001) 738-743
42. Michael M.S., Badr M.Z., and Badawi A.F. Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells. Int. J. Mol. Med. 11 (2003) 733-736
43. Badawi A.F., and Badr M.Z. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis. Int. J. Cancer 103 (2003) 84-90
44. Yang W.L., and Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22 (2001) 1379-1383
45. Lee C.J., Han J.S., Seo C.Y., Park T.H., Kwon H.C., Jeong J.S., Kim I.H., Yun J., Bae Y.S., Kwak J.Y., and Park J.I. Pioglitazone, a synthetic ligand for PPARgamma, induces apoptosis in RB-deficient human colorectal cancer cells. Apoptosis 11 (2006) 401-411
46. Clay C.E., Namen A.M., Atsumi G., Willingham M.C., High K.P., Kute T.E., Trimboli A.J., Fonteh A.N., Dawson P.A., and Chilton F.H. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 20 (1999) 1905-1911
47. Nagahara T., Okano J., and Murawaki Y. Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells. Oncol. Rep. 18 (2007) 1281-1290
48. Gelman L., Fruchart J.C., and Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell. Mol. Life Sci. 55 (1999) 932-943
49. Subbaramaiah K., Lin D.T., Hart J.C., and Dannenberg A.J. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J. Biol. Chem. 276 (2001) 12440-12448
50. Zhang Y., Tao J., Huang H., Ding G., Cheng Y., and Sun W. Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells. Pharmacol. Res. 56 (2007) 267-274
51. Chang A.J., Song D.H., and Wolfe M.M. Attenuation of peroxisome proliferator-activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation. J. Biol. Chem. 281 (2006) 14700-14710
52. Williams G.T., and Smith C.A. Molecular regulation of apoptosis: genetic controls on cell death. Cell 74 (1993) 777-779
53. Adams J.M., and Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 281 (1998) 1322-1326